Compare CODA & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CODA | ANIX |
|---|---|---|
| Founded | 1994 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 98.9M | 135.3M |
| IPO Year | N/A | 1987 |
| Metric | CODA | ANIX |
|---|---|---|
| Price | $8.92 | $3.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 48.5K | ★ 448.6K |
| Earning Date | 01-28-2026 | 01-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 15.09 | N/A |
| EPS | ★ 0.30 | N/A |
| Revenue | ★ $24,347,217.00 | N/A |
| Revenue This Year | $30.82 | N/A |
| Revenue Next Year | $20.84 | N/A |
| P/E Ratio | $31.20 | ★ N/A |
| Revenue Growth | ★ 29.34 | N/A |
| 52 Week Low | $5.76 | $2.07 |
| 52 Week High | $10.54 | $5.46 |
| Indicator | CODA | ANIX |
|---|---|---|
| Relative Strength Index (RSI) | 47.95 | 36.80 |
| Support Level | $9.15 | $3.23 |
| Resistance Level | $9.60 | $3.44 |
| Average True Range (ATR) | 0.42 | 0.38 |
| MACD | 0.02 | -0.10 |
| Stochastic Oscillator | 31.42 | 2.78 |
Coda Octopus Group Inc develops underwater technologies and equipment for imaging, mapping defense, and survey applications. The company's operations are organized into two reportable segments: the Products Segment (Marine Technology Business serving the subsea market and PAL, which sells other products (acoustic hydrophones and acoustic materials to a different market); and the Services Segment (Marine Engineering Business). Its geographical segments are the Americas, Europe, Australia/Asia, and the Middle East/Africa. The majority of revenue is derived from the Products segment.
Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.